Tofacitinib in Refractory Scleritis: A Case Series

Tofacitinib, a Janus kinase inhibitor, has been recently investigated as a potential therapy for refractory scleritis. Despite treatment with systemic immunosuppressive agents, scleritis is refractory to conventional therapy in a significant number of patients. Hereby, we report the use of tofacitin...

Descripción completa

Detalles Bibliográficos
Autores principales: Dey, Suvankar, Sarkar, Rajdeep, Pradhan, Amrita, Padhan, Prasanta, Maikap, Debashis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Mediterranean Journal of Rheumatology (MJR) 2023
Materias:
Case-Based Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10628867/
https://www.ncbi.nlm.nih.gov/pubmed/37941862
http://dx.doi.org/10.31138/mjr.20230828.ti
_version_ 1785131851741921280
author Dey, Suvankar
Sarkar, Rajdeep
Pradhan, Amrita
Padhan, Prasanta
Maikap, Debashis
author_facet Dey, Suvankar
Sarkar, Rajdeep
Pradhan, Amrita
Padhan, Prasanta
Maikap, Debashis
author_sort Dey, Suvankar
collection PubMed
description Tofacitinib, a Janus kinase inhibitor, has been recently investigated as a potential therapy for refractory scleritis. Despite treatment with systemic immunosuppressive agents, scleritis is refractory to conventional therapy in a significant number of patients. Hereby, we report the use of tofacitinib as a steroid-sparing immunomodulatory agent in three patients with refractory scleritis who were either recalcitrant or intolerant to conventional therapy.
format Online
Article
Text
id pubmed-10628867
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher The Mediterranean Journal of Rheumatology (MJR)
record_format MEDLINE/PubMed
spelling pubmed-106288672023-11-08 Tofacitinib in Refractory Scleritis: A Case Series Dey, Suvankar Sarkar, Rajdeep Pradhan, Amrita Padhan, Prasanta Maikap, Debashis Mediterr J Rheumatol Case-Based Review Tofacitinib, a Janus kinase inhibitor, has been recently investigated as a potential therapy for refractory scleritis. Despite treatment with systemic immunosuppressive agents, scleritis is refractory to conventional therapy in a significant number of patients. Hereby, we report the use of tofacitinib as a steroid-sparing immunomodulatory agent in three patients with refractory scleritis who were either recalcitrant or intolerant to conventional therapy. The Mediterranean Journal of Rheumatology (MJR) 2023-08-28 /pmc/articles/PMC10628867/ /pubmed/37941862 http://dx.doi.org/10.31138/mjr.20230828.ti Text en © 2023 The Mediterranean Journal of Rheumatology (MJR) https://creativecommons.org/licenses/by/4.0/This work is licensed under and Creative Commons Attribution-NonCommercial 4.0 International License.
spellingShingle Case-Based Review
Dey, Suvankar
Sarkar, Rajdeep
Pradhan, Amrita
Padhan, Prasanta
Maikap, Debashis
Tofacitinib in Refractory Scleritis: A Case Series
title Tofacitinib in Refractory Scleritis: A Case Series
title_full Tofacitinib in Refractory Scleritis: A Case Series
title_fullStr Tofacitinib in Refractory Scleritis: A Case Series
title_full_unstemmed Tofacitinib in Refractory Scleritis: A Case Series
title_short Tofacitinib in Refractory Scleritis: A Case Series
title_sort tofacitinib in refractory scleritis: a case series
topic Case-Based Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10628867/
https://www.ncbi.nlm.nih.gov/pubmed/37941862
http://dx.doi.org/10.31138/mjr.20230828.ti
work_keys_str_mv AT deysuvankar tofacitinibinrefractoryscleritisacaseseries
AT sarkarrajdeep tofacitinibinrefractoryscleritisacaseseries
AT pradhanamrita tofacitinibinrefractoryscleritisacaseseries
AT padhanprasanta tofacitinibinrefractoryscleritisacaseseries
AT maikapdebashis tofacitinibinrefractoryscleritisacaseseries

Ejemplares similares